CA2317811A1 - Treatment of dyskinesias - Google Patents
Treatment of dyskinesias Download PDFInfo
- Publication number
- CA2317811A1 CA2317811A1 CA002317811A CA2317811A CA2317811A1 CA 2317811 A1 CA2317811 A1 CA 2317811A1 CA 002317811 A CA002317811 A CA 002317811A CA 2317811 A CA2317811 A CA 2317811A CA 2317811 A1 CA2317811 A1 CA 2317811A1
- Authority
- CA
- Canada
- Prior art keywords
- riluzole
- levodopa
- dyskinesia
- patients
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000012661 Dyskinesia Diseases 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 title claims description 20
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 33
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960004502 levodopa Drugs 0.000 claims abstract description 33
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960004181 riluzole Drugs 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 239000003196 psychodysleptic agent Substances 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 230000003291 dopaminomimetic effect Effects 0.000 description 8
- 239000003176 neuroleptic agent Substances 0.000 description 8
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 6
- 208000015592 Involuntary movements Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 206010008748 Chorea Diseases 0.000 description 2
- 208000024453 abnormal involuntary movement Diseases 0.000 description 2
- 229940035678 anti-parkinson drug Drugs 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010008752 Choreiform movements Diseases 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000003954 decarboxylase inhibitor Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229940052740 other dopaminergic agent in atc Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL122883 | 1998-01-09 | ||
| IL12288398A IL122883A0 (en) | 1998-01-09 | 1998-01-09 | Pharmaceutical compositions for the treatment of dyskinesias |
| IL12710298A IL127102A0 (en) | 1998-11-17 | 1998-11-17 | Pharmaceutical compositions for the treatment of dyskinesias |
| PCT/IL1999/000003 WO1999034785A2 (en) | 1998-01-09 | 1999-01-05 | Treatment of dyskinesias |
| IL127102 | 1999-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2317811A1 true CA2317811A1 (en) | 1999-07-15 |
Family
ID=26323572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002317811A Abandoned CA2317811A1 (en) | 1998-01-09 | 1999-01-05 | Treatment of dyskinesias |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1043996A2 (enExample) |
| JP (1) | JP2002500181A (enExample) |
| KR (1) | KR20010033978A (enExample) |
| CN (1) | CN1290166A (enExample) |
| AU (1) | AU1780699A (enExample) |
| BR (1) | BR9906821A (enExample) |
| CA (1) | CA2317811A1 (enExample) |
| NO (1) | NO20003529L (enExample) |
| PL (1) | PL342098A1 (enExample) |
| WO (1) | WO1999034785A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2790670A1 (fr) * | 1999-03-12 | 2000-09-15 | Aventis Pharma Sa | Association riluzole et antagoniste des recepteurs ampa |
| WO2000054772A1 (fr) * | 1999-03-12 | 2000-09-21 | Aventis Pharma S.A. | Traitement de la sclerose laterale amyotrophique avec une association de riluzole et d'un antagoniste des recepteurs ampa |
| US6297254B1 (en) | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
| FR2801793B1 (fr) * | 1999-12-01 | 2003-07-04 | Aventis Pharma Sa | Association d'une ergoline et de riluzole et son utilisation comme medicament |
| FR2809620B1 (fr) * | 2000-06-05 | 2002-08-02 | Aventis Pharma Sa | Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie |
| ES2203563T3 (es) * | 2001-05-08 | 2004-04-16 | Schwarz Pharma Ag | Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
-
1999
- 1999-01-05 JP JP2000527236A patent/JP2002500181A/ja active Pending
- 1999-01-05 CA CA002317811A patent/CA2317811A1/en not_active Abandoned
- 1999-01-05 BR BR9906821-4A patent/BR9906821A/pt not_active IP Right Cessation
- 1999-01-05 AU AU17806/99A patent/AU1780699A/en not_active Abandoned
- 1999-01-05 WO PCT/IL1999/000003 patent/WO1999034785A2/en not_active Ceased
- 1999-01-05 CN CN99802790A patent/CN1290166A/zh active Pending
- 1999-01-05 PL PL99342098A patent/PL342098A1/xx unknown
- 1999-01-05 KR KR1020007007567A patent/KR20010033978A/ko not_active Withdrawn
- 1999-01-05 EP EP99900116A patent/EP1043996A2/en not_active Withdrawn
-
2000
- 2000-07-07 NO NO20003529A patent/NO20003529L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002500181A (ja) | 2002-01-08 |
| EP1043996A2 (en) | 2000-10-18 |
| AU1780699A (en) | 1999-07-26 |
| WO1999034785A2 (en) | 1999-07-15 |
| NO20003529L (no) | 2000-09-08 |
| PL342098A1 (en) | 2001-05-21 |
| WO1999034785A3 (en) | 1999-09-16 |
| BR9906821A (pt) | 2000-10-17 |
| KR20010033978A (ko) | 2001-04-25 |
| NO20003529D0 (no) | 2000-07-07 |
| CN1290166A (zh) | 2001-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250248962A1 (en) | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones | |
| WO2006053186A2 (en) | Method for treatment of movement disorders | |
| JP2005527599A (ja) | 肥満および摂食障害におけるゾニサミドの使用 | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| DE19818563C2 (de) | Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung | |
| EP1737438B1 (en) | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome | |
| US6417210B1 (en) | Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa | |
| CA2317811A1 (en) | Treatment of dyskinesias | |
| CN114432266A (zh) | 一种稳定的盐酸环苯扎林缓释胶囊 | |
| MXPA00006800A (en) | Treatment of dyskinesias | |
| Rudick et al. | Drug treatment of multiple sclerosis | |
| ZA200509665B (en) | Use of tripolidine in a providing refreshedness on waking | |
| US20240165124A1 (en) | Combination therapy for treating executive function disorders | |
| HK1260409B (en) | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones | |
| HK1260409A1 (en) | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |